Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734
Shots:
- Eikon gets an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excl. Greater China (mainland China, Hong Kong, Macau, and Taiwan)
- The collaboration will combine Impact and Eikon's scientific, clinical, regulatory expertise and financial resources to advance the development of the PARP1 selective inhibitor program & bring new cancer therapies for patients in China and globally
- Additionally, the P-I study of IMP1734 is expected to be initiated in 2023. IMP1734 showed a high anti-tumor activity and a wide therapeutic window in the preclinical in vivo models
Ref: prnewswire | Image: Impact Therapeutics
Related News:- IMPACT Therapeutics’ IMP4297 and Temozolomide Receives the US FDA’s Orphan Drug Designation for Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
